Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

RECEIVED. SECRETARY OF THE SENATE

04 AUG 16 PM 1:52

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name			
O'Connor & Hannan, L.L.	P.		
2. Registrant Address	different than previously reported State/Zip (or Country)	Suite 500 DC 20006	
3. Principal Place of Business (if differ	ent from line 2)		
City	State/Zip (or Country)		
4. Contact Name	Telephone E-m	ail (optional)	5. Senate ID#
Timothy W. Jenkins	(202) 887-1400		29846-1992
7. Client Name Self			6. House ID #
Merck & Co., Inc.		30352156	
INCOME OR EXPE	•		
12. Lobbying Firms		13. Organizations	
INCOME relating to lobbying activities for this reporting period was:		EXPENSES relating to lobbying activities for this repoperiod were:	
Less than \$10,000 □		Less than \$10,000	
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING METHOD. Check accounting method. See instructions fo Method A. Reporting amounts usi Method B. Reporting amounts und			
for lobbying activities on behali	income from the client egistrant by any other entity	☐ Method A. Reporting amounts	for description of ousing LDA definition under section 6033

Filing #8d5d2bad-5340-4feb-aa30-f5a157292315 - Page 1 of 6

Data 8/13/2004

Signature	Date	
Printed Name and Title Timothy W. Jenkins - Partner	P	ag
		ب

00000771882

Reg	istrant Name:	O'Connor & Hannan, L.L.P.			
Clie	nt Name:	Merck & Co., Inc.			
enga	iged in lobbyin		ary to reflect the general issue areas in which the registrant ting period. Using a separate page for each code, provide ed.		
15.	5. General issue area code HCR (one per page)				
16.	6. Specific Lobbying issues H.R. 1 Medicare Prescription Drug and Modernization Act of 2003 (including reimportation provisions); H. Pharmaceutical Market Access of 2003; S. 1 Prescription Drug and Medicare Improvement Act of 2003; Dr Importation Promotion and Safety Act (Introduced in House)[H.R.4790.IH]; Safe IMPORT Act of 2004 (Int House)[H.R.4923.IH]; To amend the Federal Food, Drug, and Cosmetic Act with respect to the importation prescription drugs. (Introduced in House)[H.R.3710.IH]; Expressing the sense of the Congress that the illegs of prescription drugs severely undermines the regulatory protections afforded to United States consumers, a other (Introduced in House)[H.CON.RES.225.IH]; Save Our Seniors Act of 2003 (Introduced in House)[H. Prescription Drug Parity for Americans Act (Introduced in House)[H.R.2497.IH]; Affordable Medicine Safe Act (Introduced in House)[H.R.2717.IH]; Reliable Entry for Medicines at Everyday Discounts through Imp Effective Safeguards Act of 2004 (Introduced in Senate)[S.2307.IS];				
17.	House(s) of C House of Re Senate	Congress and Federal agencies contacted presentatives	☐ Check if None		
18.	Name of each	n individual who acted as a lobbyist in thi	s issue area		
	Name		Covered Official Position (if applicable)		
	Jenkins, Tim	nothy W.			
19.	Interest of ea	ch foreign entity in the specific issues list	red on line 16 above 🔀 Check if None		

Data 8/13/2004

0:-----

Signature		Date	
Printed Name and Title	Timothy W. Jenkins - Partner		Pag

00000771883

Registrant N	lame: O'Connor & Hannan, L.L.	<u>P.</u>			
Client Name	Merck & Co., Inc.				
engaged in l	· · · · · · · · · · · · · · · · · · ·	as necessary to reflect the general issue areas in which the registrant g the reporting period. Using a separate page for each code, provide (s) as needed.			
16. Specifi H.R. 1 Pharm Import House) prescri of pres other Prescr. Act (In	H.R. 1 Medicare Prescription Drug and Modernization Act of 2003 (including reimportation provisions); H. Pharmaceutical Market Access of 2003; S. 1 Prescription Drug and Medicare Improvement Act of 2003; Drug Importation Promotion and Safety Act (Introduced in House)[H.R.4790.IH]; Safe IMPORT Act of 2004 (Introduce)[H.R.4923.IH]; To amend the Federal Food, Drug, and Cosmetic Act with respect to the importation prescription drugs. (Introduced in House)[H.R.3710.IH]; Expressing the sense of the Congress that the illegated of prescription drugs severely undermines the regulatory protections afforded to United States consumers, a other (Introduced in House)[H.CON.RES.225.IH]; Save Our Seniors Act of 2003 (Introduced in House)[H. Prescription Drug Parity for Americans Act (Introduced in House)[H.R.2497.IH]; Affordable Medicine Safe Act (Introduced in House)[H.R.2717.IH]; Reliable Entry for Medicines at Everyday Discounts through Important Effective Safeguards Act of 2004 (Introduced in Senate)[S.2307.IS];				
	(s) of Congress and Federal agencies of Representatives	contacted Check if None			
	of each individual who acted as a lob	byist in this issue area Covered Official Position (if applicable)			
Name		Covered Official Position (II applicable)			
Jenkin	s, Timothy W.				
19. Interes	t of each foreign entity in the specifi	c issues listed on line 16 above Check if None			

Date 8/13/2004

er 1 1 a

отдиатите		Date	
Printed Name and Title	Timothy W. Jenkins - Partner		Pag